Population Diagnostics discovers causative genetic biomarkers to:
- Develop and market DNA-based diagnostic tests for pre-symptomatic early detection of disease.
- Enable pharmaceutical companies to develop companion diagnostics and novel targeted drugs with greater efficacy and safety.
Population Diagnostics has intellectual property portfolios in Parkinson’s disease and Autism Spectrum Disorder comprising causative biomarker collections for both therapeutic and diagnostics applications. In addition to active discovery programs in a variety of diseases (see figure), our technology highly enables the cytogenetics diagnostic market. Population Diagnostics pursues alliances with microarray providers serving the cytogenetics community.